Impact of bivalirudin on mortality and bleeding complications in acute coronary syndrome patients undergoing invasive revascularization : A real world experience.
CONCLUSIONS: This retrospective analysis in a real world situation of medium to high-risk ACS patients undergoing invasive revascularization confirmed the results of most large-scale randomized trials by demonstrating reduced bleeding rates in favor of bivalirudin vs. UFH + GPI but with no significant differences between treatment strategies for long-term all-cause and cardiovascular mortality.
PMID: 27624328 [PubMed - as supplied by publisher]
Source: Wiener Klinische Wochenschrift - Category: Journals (General) Authors: Rohla M, Tentzeris I, Freynhofer MK, Farhan S, Jarai R, Egger F, Weiss TW, Wojta J, Geppert A, Kastrati A, Stone GW, Huber K Tags: Wien Klin Wochenschr Source Type: research
More News: Abciximab | Angiomax | Bleeding | Cardiology | Cardiovascular | General Medicine | Heart | Thrombosis